RATIONALE-309: Updated progresssion -free survival from a phase 3 double-blind trail of tislelizumab versus placebo, plus chemotherapy, as first -line treatment for recurrent/metastatic nasopharyngeal cancer.

被引：0
|
作者：
Zhang, Li
Yang, Yunpeng
Pan, Jian-Ji
Chen, Xiaozhong
Sun, Yan
Wang, Hui
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 36期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] Randomized Double-Blind Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer
    Galsky, Matthew D.
    Mortazavi, Amir
    Milowsky, Matthew, I
    George, Saby
    Gupta, Sumati
    Fleming, Mark T.
    Dang, Long H.
    Geynisman, Daniel M.
    Walling, Radhika
    Alter, Robert S.
    Kassar, Mohamad
    Wang, Jue
    Gupta, Shilpa
    Davis, Nancy
    Picus, Joel
    Philips, George
    Quinn, David, I
    Haines, G. Kenneth, III
    Hahn, Noah M.
    Zhao, Qianqian
    Yu, Menggang
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (16) : 1797 - +
  • [22] A randomized, double-blind, placebo-controlled phase III study to evaluate AK104 plus platinum-containing chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer.
    Wu, Xiaohua
    Wang, Jing
    Huang, Yi
    Li, Yuzhi
    Sun, Yang
    Wang, Ke
    Xia, Michelle
    Li, Baiyong
    Liu, Wei
    CANCER RESEARCH, 2022, 82 (12)
  • [23] Global, randomized, phase III study of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced/metastatic esophageal squamous cell carcinoma (RATIONALE-306 update): Minimum 3-year survival follow-up
    Yoon, Harry H.
    Kato, Ken
    Raymond, Eric
    Hubner, Richard
    Shu, Yongqian
    Pan, Yueyin
    Jiang, Yi
    Zhang, Jingdong
    Park, Sook Ryun
    Kojima, Takashi
    Lin, Chen-Yuan
    Wyrwicz, Lucjan S.
    Tougeron, David
    Ishihara, Ryu
    Li, Liyun
    Wu, Hongqian
    Peng, Yanyan
    Yan, Shican
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] A randomized, double-blind, phase II study of first-line FOLFOX plus bevacizumab with onartuzumab versus placebo in patients with metastatic colorectal cancer (mCRC).
    Bendell, Johanna C.
    Hochster, Howard S.
    Hart, Lowell L.
    Firdaus, Irfan
    Mace, Joseph Ronald
    McFarlane, Joshua Jemison
    Kozloff, Mark
    Catenacci, Daniel Virgil Thomas
    Hsu, Jessie J.
    Hack, Stephen Paul
    Shames, David S.
    Phan, See-Chun
    Cohn, Allen Lee
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [25] Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study
    Robert, Caroline
    Dummer, Reinhard
    Gutzmer, Ralf
    Lorigan, Paul
    Kim, Kevin B.
    Nyakas, Marta
    Arance, Ana
    Liszkay, Gabriella
    Schadendorf, Dirk
    Cantarini, Mireille
    Spencer, Stuart
    Middleton, Mark R.
    LANCET ONCOLOGY, 2013, 14 (08): : 733 - 740
  • [26] KEYNOTE-355: Final results from a randomized, double-blind phase III study of first-line pembrolizumab plus chemotherapy vs placebo plus chemotherapy for metastatic TNBC
    Cortes, J.
    Cescon, D. W.
    Rugo, H. S.
    Im, S-A.
    Yusof, M. Md
    Gallardo, C.
    Lipatov, O.
    Barrios, C. H.
    Perez-Garcia, J.
    Iwata, H.
    Masuda, N.
    Otero, M. Torregroza
    Gokmen, E.
    Loi, S.
    Guo, Z.
    Zhou, X.
    Karantza, V.
    Pan, W.
    Schmid, P.
    ANNALS OF ONCOLOGY, 2021, 32 : S1289 - S1290
  • [27] Tislelizumab versus placebo combined with induction chemotherapy followed by concurrent chemoradiotherapy and adjuvant tislelizumab or placebo for locoregionally advanced nasopharyngeal carcinoma: Interim analysis of a multicenter, randomized, placebo-controlled, double-blind, phase 3 trial.
    Mai, Hai-Qiang
    Liu, Sai Lan
    Chen, Qiu-Yan
    Tang, Lin-Quan
    Jin, Feng
    Guo, Ling
    Luo, Haiqing
    Hu, Ying
    Liu, Huai
    Liang, Jin-Hui
    Zhao, Chong
    Luo, Dong-Hua
    Mo, Hao-Yuan
    Guo, Shan-Shan
    Liu, Li-Ting
    Li, Ji-Bin
    Wang, Lin
    Sun, Xue-Song
    Li, Xiao-Yun
    Wang, Pan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] First-Line Pembrolizumab plus Chemotherapy Versus Placebo plus Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
    Monk, Bradley J.
    Colombo, Nicoletta
    Tewari, Krishnansu S.
    Dubot, Coraline
    Caceres, M. Valeria
    Hasegawa, Kosei
    Shapira-Frommer, Ronnie
    Salman, Pamela
    Yanez, Eduardo
    Gumus, Mahmut
    de Mendoza, Mivael Olivera Hurtado
    Samouelian, Vanessa
    Castonguay, Vincent
    Arkhipov, Alexander
    Tekin, Cumhur
    Li, Kan
    Keefe, Stephen M.
    Lorusso, Domenica
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (36) : 5505 - +
  • [29] Delta tocotrienol as a supplement to FOLFOXIRI in first-line treatment of metastatic colorectal cancer. A randomized, double-blind, placebo-controlled phase II study
    Raunkilde, Louise
    Hansen, Torben Frostrup
    Havelund, Birgitte Mayland
    Thomsen, Caroline Brenner
    Rafaelsen, Soren Rafael
    Lindebjerg, Jan
    Jensen, Lars Henrik
    ACTA ONCOLOGICA, 2023, 62 (09) : 1066 - 1075
  • [30] Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
    Cortes, Javier
    Cescon, David W.
    Rugo, Hope S.
    Nowecki, Zbigniew
    Im, Seock-Ah
    Yusof, Mastura Md
    Gallardo, Carlos
    Lipatov, Oleg
    Barrios, Carlos H.
    Holgado, Esther
    Iwata, Hiroji
    Masuda, Norikazu
    Torregroza Otero, Marco
    Gokmen, Erhan
    Loi, Sherene
    Guo, Zifang
    Zhao, Jing
    Aktan, Gursel
    Karantza, Vassiliki
    Schmid, Peter
    LANCET, 2020, 396 (10265): : 1817 - 1828
12345